Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Inclusion Criteria:

1. Male or female patients aged 14 years or older

2. Newly diagnosed Philadelphia chromosome positive(either t(9;22) and/or BCR-ABLpositive and/ or FISH positive) acute lymphoblastic leukemia; Patients will bediagnosed according to morphologic,immunologic, cytogenetic and molecular(MICM)criteria, including bone marrow morphology, immunophenotype, cytogenetic andmolecular genetic (BCR/ABL gene, qualitative and quantitative analysis) examination

3. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2

4. Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x upper limit ofnormal（ULN）; serum alanine aminotransferase (ALT) and serum aspartateaminotransferase (AST) ≤ 2.5 x ULN or ≤5 x ULN if leukemic involvement of the liveris present; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkalinephosphatase ≤ 2.5 x ULN unless considered tumor related; normal electrolytes:Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN; Cardiac color Doppler ultrasoundejection fraction ≥ 45%;

5. Subject has provided written informed consent prior to any screening procedure

Exclusion Criteria:

1. Lymphoid blast crisis of chronic myelocytic leukemia (CML)

2. Previous or ongoing systemic anti-ALL therapy (including but not restricted to TKIand/or radiotherapy, except for appropriate pre-treatment)

3. Clinical manifestations of CNS or extramedullary involvement with ALL

4. Patients with a history of myocardial infarction within 12 months or clinicallysignificant cardiac disorders disease (e.g., unstable angina, congestive heartfailure, uncontrollable hypertension, uncontrollable arrhythmia, etc.)

5. Uncontrolled active serious infections that could, in the investigator's opinion,potentially interfere with the completion of treatment

6. Known HIV seropositivity

7. History of acute pancreatitis within 1 year of study screening or history of chronicpancreatitis

8. Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)

9. Female patients who are pregnant or breast feeding

10. Poorly controlled diabetes, defined as glycosylated hemoglobin (HbA1c) values of >7.5%. Patients with preexisting, well-controlled diabetes are not excluded

11. Any serious psychiatric illness that could, in the investigator's opinion,potentially interfere with the completion of treatment